4 Mar

Why the CRISPR-Cas9 patent battle matters less than people think

New interferences involving ToolGen mean that the fight over fundamental Cas9 rights is unlikely to end any time soon. But rapid developments in the CRISPR space are making the dispute’s outcome less significant than was previously thought.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth